Wire · opportunities
Sevabertinib Moves Into First-Line HER2-Mutant NSCLC With FDA Accelerated Approval
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 September 2026 · Fusion42 review
The FDA granted accelerated approval to sevabertinib for first-line treatment of adults with locally advanced or metastatic non-squamous NSCLC harboring HER2 tyrosine kinase domain activating mutations, expanding its use beyond previously treated patients.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 9 Sep 2026 and 10 Sep 2026.
◆ ◆ The Wire takeaway
You must prioritise molecular testing for HER2 mutations in NSCLC to access first-line sevabertinib treatment. This approval changes treatment sequencing and opens a market for upfront targeted therapies in this patient subgroup.
◆ Coverage
7 sources · first reported 9 Sep 2026 · latest 10 Sep 2026
◆ Topics